Phase II trial of carboplatin plus oral etoposide for elderly patients with small-cell lung cancer.
A phase II trial was conducted to evaluate the efficacy and toxicity of the Egorin's carboplatin dosing formula with 14-day oral etoposide in 38 elderly patients with small-cell lung cancer (SCLC). The overall response rate was 81%. Median survival times were 15.1 months for 16 limited-disease...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
Nature Publishing Group
1998
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2150367/ |